(2S)-2-benzyl 1-tert-butyl 5-allylpyrrolidine-1,2-dicarboxylate | 1383616-54-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-benzyl 1-tert-butyl 5-allylpyrrolidine-1,2-dicarboxylate
• 英文别名: 2-O-benzyl 1-O-tert-butyl 5-prop-2-enylpyrrolidine-1,2-dicarboxylate
• CAS: 1383616-54-3
• 化学式: C₂₀H₂₇NO₄
• 分子量: 345.439
• InChiKey: FXRGXJQRQWOLLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S)-2-benzyl 1-tert-butyl 5-allylpyrrolidine-1,2-dicarboxylate 在 Hoveyda-Grubbs catalyst second generation 、 palladium on activated charcoal 、 氢气 、 三乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 Benzyl 3-benzyl-5-oxo-1,2,6,7,8,8a-hexahydroindolizine-3-carboxylate
  参考文献：
  名称：

  Towards a KCC2 blocker pharmacophore model

  摘要：

  A multi-disciplinary approach was used to identify the first pharmacophore model for KCC2 blockers: several physico-chemical studies such as XRD and NMR were combined to molecular modelling techniques, SAR analysis and synthesis of constrained analogues in order to determine a minimal conformational space regrouping few potential bioactive conformations. These conformations were further compared to the conformational space of a different series of KCC2 blockers in order to identify the common pharmacophoric features. The synthesis of more potent analogues in this second series confirmed the usefulness of this KCC2 blocker pharmacophore model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.097
• 作为产物：
  描述：

  (2S)-2-benzyl 1-tert-butyl 5-methoxypyrrolidine-1,2-dicarboxylate 、 三氟化硼乙醚 以 二氯甲烷 、 水 为溶剂， 生成 (2S)-2-benzyl 1-tert-butyl 5-allylpyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN

  摘要：

  本发明涉及酶抑制剂。更具体地说，本发明涉及配体导向的蛋白共价修饰；相同设计方法；相同的药物配方；以及使用方法。

  公开号：

  US20110269244A1

文献信息

• Ligand-Directed Covalent Modification of Protein
  申请人：Celgene CAR LLC

  公开号：US20170218353A1

  公开（公告）日：2017-08-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
• [EN] LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN<br/>[FR] MODIFICATION COVALENTE DE PROTÉINE, DIRIGÉE SUR UN LIGAND
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011082285A1

  公开（公告）日：2011-07-07

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
• LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN
  申请人：Petter Russell C.

  公开号：US20110269244A1

  公开（公告）日：2011-11-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

  本发明涉及酶抑制剂。更具体地说，本发明涉及配体导向的蛋白共价修饰；相同设计方法；相同的药物配方；以及使用方法。
• Towards a KCC2 blocker pharmacophore model
  作者：Florence Lebon、Cécile Pégurier、Marie Ledecq、Benoit Mathieu、Nathalie Bosman、Anne Frycia、Sébastien Lengelé、Kashinath Dhurke、Ananda Kumar Kanduluru、Stéphane Meunier、Alain Wagner、Christian Wolff、Laurent Provins

  DOI：10.1016/j.bmcl.2012.04.097

  日期：2012.6

  A multi-disciplinary approach was used to identify the first pharmacophore model for KCC2 blockers: several physico-chemical studies such as XRD and NMR were combined to molecular modelling techniques, SAR analysis and synthesis of constrained analogues in order to determine a minimal conformational space regrouping few potential bioactive conformations. These conformations were further compared to the conformational space of a different series of KCC2 blockers in order to identify the common pharmacophoric features. The synthesis of more potent analogues in this second series confirmed the usefulness of this KCC2 blocker pharmacophore model. (C) 2012 Elsevier Ltd. All rights reserved.